Academic Journal
CD58 expression does not impact response to inotuzumab ozogamicin in patients with B‐cell acute lymphoblastic leukemia
| العنوان: | CD58 expression does not impact response to inotuzumab ozogamicin in patients with B‐cell acute lymphoblastic leukemia |
|---|---|
| المؤلفون: | Madero‐Marroquin, Rafael, Hunter, Ryan W., Saygin, Caner, Johnston, Hannah, DuVall, Adam S., Rahmani Youshanlouei, Hamed, Osei, Clinton, Shah, Syed, Stock, Wendy, Gurbuxani, Sandeep, Patel, Anand A. |
| المصدر: | eJHaem ; volume 6, issue 1 ; ISSN 2688-6146 2688-6146 |
| بيانات النشر: | Wiley |
| سنة النشر: | 2024 |
| المجموعة: | Wiley Online Library (Open Access Articles via Crossref) |
| الوصف: | Background CD58 loss has been described as a mechanism of resistance to blinatumomab and chimeric antigen receptor T‐cell therapy, functioning as a modulator of response to T‐cell activation. Methods Using flow cytometry, we evaluated the impact of CD58 mean fluorescence intensity (MFI) on the probability of achieving measurable residual disease (MRD) negativity in patients with B‐cell acute lymphoblastic leukemia treated with inotuzumab ozogamicin (InO). Results The odds ratio of achieving MRD negativity was 1.03 for every 1000 unit increase in CD58 MFI. Conclusion Our results suggest that MRD negativity rates after InO are high, regardless of the intensity of CD58 expression. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1002/jha2.1076 |
| الاتاحة: | https://doi.org/10.1002/jha2.1076 https://onlinelibrary.wiley.com/doi/pdf/10.1002/jha2.1076 |
| Rights: | http://creativecommons.org/licenses/by/4.0/ |
| رقم الانضمام: | edsbas.80C722DA |
| قاعدة البيانات: | BASE |
| DOI: | 10.1002/jha2.1076 |
|---|